GREENWICH
GW Pharma Limited
Application Filed: 2018-04-24
Trademark Application Details
PUBLICATION/ISSUE REVIEW COMPLETE
| Research |
OneLook
Acronym Finder
|
| Serial Number | 79237055 |
| Registration Number | 6031354 |
| Mark Drawing Code | 4000: Illustration: Drawing with word(s)/letter(s)/number(s) in Block form |
| Attorney Name | Jennifer M. Hetu |
| Attorney Docket Number | 224143438449 |
| Law Office Assigned | L80 |
| Employee Name | LOOK, JEFFREY J |
Timeline
| 2018-04-24 | Application Filed |
| 2019-12-26 | Location: PUBLICATION AND ISSUE SECTION |
| 2019-12-26 | Status: Live/Pending |
| 2019-12-27 | Transaction Date |
| 2020-01-28 | Published for Opposition |
| 2020-04-14 | Trademark Registered |
Trademark Applicants & Owners
| Owner: |  GW Pharma Limited |
| Address | Sovereign House Histon, Cambridge CB24 9BZ GB |
| Legal Entity Type | Limited Liability Limited Partnership |
| Legal Entity State | GB |
Documents
Click the blue "Refresh" button to load certificates, specimines, application, and other documents.
Attorney of Record
Good, Services, and Codes
| International Codes: | 5 |
| U.S. Codes: | 006,018,044,046,051,052 |
| Type Code | Type |
|---|---|
| GS0051 | Pharmaceutical and medical preparations and substances in the nature of a drug product in finished dosage formulation that contains cannabidiol derived from cannabis and no more than 0.1 percent residual tetrahydrocannabinols, for the treatment of Dravet Syndrome and Lennox-Gestaut Syndrome; pharmaceutical and medical preparations with cannabinoids as active ingredient, namely, a drug product in finished dosage formulation that contains cannabidiol derived from cannabis and no more than 0.1 percent residual tetrahydrocannabinols for the treatment of Dravet Syndrome and Lennox-Gestaut Syndrome; pharmaceutical preparations and substances for the treatment of epilepsy associated with Dravet Syndrome and Lennox-Gestaut Syndrome in the nature of a drug product in finished dosage formulation that contains cannabidiol derived from cannabis and no more than 0.1 percent residual tetrahydrocannabinols; pharmaceutical preparations and substances for the treatment of convulsions and seizures associated with epilepsy associated with Dravet Syndrome and Lennox-Gestaut Syndrome in the nature of a drug product in finished dosage formulation that contains cannabidiol derived from cannabis and no more than 0.1 percent residual tetrahydrocannabinols; pharmaceutical and medical preparations for the treatment of symptoms associated with epilepsy including pain, muscle spasticity and spasms, bladder problems and sleep disorders associated with Dravet Syndrome and Lennox-Gestaut Syndrome in the nature of a drug product in finished dosage formulation that contains cannabidiol derived from cannabis and no more than 0.1 percent residual tetrahydrocannabinols; medicinal oils in the nature of a drug product in finished dosage formulation that contains cannabidiol derived from cannabis and no more than 0.1 percent residual tetrahydrocannabinols for the treatment of Dravet Syndrome and Lennox-Gestaut Syndrome; medicinal infusions in the nature of a drug product in finished dosage formulation that contains cannabidiol derived from cannabis and no more than 0.1 percent residual tetrahydrocannabinols for the treatment of epilepsy, convulsions and seizures associated with Dravet Syndrome and Lennox-Gestaut Syndrome |
| GS0051 | Pharmaceutical and medical preparations and substances in the nature of a drug product in finished dosage formulation that contains cannabidiol derived from cannabis and no more than 0.1 percent residual tetrahydrocannabinols, for the treatment of Dravet Syndrome and Lennox-Gestaut Syndrome; pharmaceutical and medical preparations with cannabinoids as active ingredient, namely, a drug product in finished dosage formulation that contains cannabidiol derived from cannabis and no more than 0.1 percent residual tetrahydrocannabinols for the treatment of Dravet Syndrome and Lennox-Gestaut Syndrome; pharmaceutical preparations and substances for the treatment of epilepsy associated with Dravet Syndrome and Lennox-Gestaut Syndrome in the nature of a drug product in finished dosage formulation that contains cannabidiol derived from cannabis and no more than 0.1 percent residual tetrahydrocannabinols; pharmaceutical preparations and substances for the treatment of convulsions and seizures associated with epilepsy associated with Dravet Syndrome and Lennox-Gestaut Syndrome in the nature of a drug product in finished dosage formulation that contains cannabidiol derived from cannabis and no more than 0.1 percent residual tetrahydrocannabinols; pharmaceutical and medical preparations for the treatment of symptoms associated with epilepsy including pain, muscle spasticity and spasms, bladder problems and sleep disorders associated with Dravet Syndrome and Lennox-Gestaut Syndrome in the nature of a drug product in finished dosage formulation that contains cannabidiol derived from cannabis and no more than 0.1 percent residual tetrahydrocannabinols; medicinal oils in the nature of a drug product in finished dosage formulation that contains cannabidiol derived from cannabis and no more than 0.1 percent residual tetrahydrocannabinols for the treatment of Dravet Syndrome and Lennox-Gestaut Syndrome; medicinal infusions in the nature of a drug product in finished dosage formulation that contains cannabidiol derived from cannabis and no more than 0.1 percent residual tetrahydrocannabinols for the treatment of epilepsy, convulsions and seizures associated with Dravet Syndrome and Lennox-Gestaut Syndrome |
Trademark Filing History
| Description | Date | Event Coding |
|---|---|---|
| SN ASSIGNED FOR SECT 66A APPL FROM IB | 2018-07-19 | 1 REPR M: |
| NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM | 2018-07-24 | 2 NWOS I:Incoming Correspondence |
| APPLICATION FILING RECEIPT MAILED | 2018-07-28 | 3 MAFR O:Outgoing Correspondence |
| ASSIGNED TO EXAMINER | 2018-08-14 | 4 DOCK D:Assigned to Examiner |
| NON-FINAL ACTION WRITTEN | 2018-08-21 | 5 CNRT R:Renewal |
| NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | 2018-08-22 | 6 RFCR E:E-Mail |
| ASSIGNED TO EXAMINER | 2018-08-27 | 7 DOCK D:Assigned to Examiner |
| NON-FINAL ACTION (IB REFUSAL) WITHDRAWN FOR REVIEW | 2018-08-29 | 8 RFWR P: |
| ASSIGNED TO EXAMINER | 2018-08-30 | 9 DOCK D:Assigned to Examiner |
| ASSIGNED TO EXAMINER | 2018-09-06 | 10 DOCK D:Assigned to Examiner |
| NON-FINAL ACTION WRITTEN | 2018-09-11 | 11 CNRT R:Renewal |
| NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | 2018-09-12 | 12 RFCR E:E-Mail |
| REFUSAL PROCESSED BY MPU | 2018-09-18 | 13 RFRR P: |
| NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | 2018-09-19 | 14 RFCS P: |
| REFUSAL PROCESSED BY IB | 2018-10-07 | 15 RFNT P: |
| TEAS RESPONSE TO OFFICE ACTION RECEIVED | 2019-03-18 | 16 TROA I:Incoming Correspondence |
| CORRESPONDENCE RECEIVED IN LAW OFFICE | 2019-03-18 | 17 CRFA I:Incoming Correspondence |
| TEAS/EMAIL CORRESPONDENCE ENTERED | 2019-03-19 | 18 TEME I:Incoming Correspondence |
| FINAL REFUSAL WRITTEN | 2019-06-20 | 19 CNFR R:Renewal |
| FINAL REFUSAL E-MAILED | 2019-06-20 | 20 GNFR O:Outgoing Correspondence |
| NOTIFICATION OF FINAL REFUSAL EMAILED | 2019-06-20 | 21 GNFN O:Outgoing Correspondence |
| EXAMINERS AMENDMENT -WRITTEN | 2019-12-19 | 22 CNEA R:Renewal |
| EXAMINERS AMENDMENT E-MAILED | 2019-12-19 | 23 GNEA O:Outgoing Correspondence |
| NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | 2019-12-19 | 24 GNEN O:Outgoing Correspondence |
| EXAMINER'S AMENDMENT ENTERED | 2019-12-19 | 25 XAEC I:Incoming Correspondence |
| APPROVED FOR PUB - PRINCIPAL REGISTER | 2019-12-20 | 26 CNSA O:Outgoing Correspondence |
| ASSIGNED TO LIE | 2019-12-23 | 27 ALIE A:Allowance for Publication |
| NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | 2019-12-25 | 28 OPNR P: |
| NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | 2019-12-25 | 29 OPNS P: |
| NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | 2020-01-08 | 30 NONP E:E-Mail |
| NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | 2020-01-08 | 31 OP2R P: |
| NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | 2020-01-08 | 32 OPNS P: |
| NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | 2020-01-10 | 33 OPNX P: |
| NOTIFICATION PROCESSED BY IB | 2020-01-24 | 34 GPNX P: |
| PUBLISHED FOR OPPOSITION | 2020-01-28 | 35 PUBO A:Allowance for Publication |
| OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | 2020-01-28 | 36 NPUB E:E-Mail |
| REGISTERED-PRINCIPAL REGISTER | 2020-04-14 | 37 R.PR A:Allowance for Publication |
| FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | 2020-07-14 | 38 FICR P: |
| FINAL DISPOSITION PROCESSED | 2020-08-17 | 39 FIMP P: |
| FINAL DISPOSITION NOTICE SENT TO IB | 2020-08-17 | 40 FICS P: |
| FINAL DECISION TRANSACTION PROCESSED BY IB | 2020-09-05 | 41 FINO P: |
| TEAS CHANGE OF OWNER ADDRESS RECEIVED | 2021-09-15 | 42 COAR I:Incoming Correspondence |
| TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | 2021-09-15 | 43 REAP I:Incoming Correspondence |
| ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | 2021-09-15 | 44 ARAA I:Incoming Correspondence |
| TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS | 2021-09-15 | 45 ECDR I:Incoming Correspondence |
| TEAS CHANGE OF CORRESPONDENCE RECEIVED | 2021-09-15 | 46 TCCA I:Incoming Correspondence |
| APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | 2021-09-15 | 47 CHAN I:Incoming Correspondence |
| NEW REPRESENTATIVE AT IB RECEIVED | 2021-11-20 | 48 NREP P: |
Similar Marks
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.
| 